Clinical study of Fei-Yan-Ning Granule delaying EGFR-targeted drug resistance for lung cancer

onghua Hospital, Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Patients with stage IIIA-IV lung adenocarcinoma confirmed by pathology or cytology or patients with postoperative recurrence and metastasis;
•(2) EGFR detected sensitive types (18, 19, 21 exon mutations);
•(3) Evaluate the disease progression after 1 month of gefitinib treatment and continue to take it;
•(4) TCM syndrome differentiation belongs to the deficiency of essence and qi;
•(5) Aged >= 18 years;
•(6) Expected survival >= 3 months;
•(7) Sign the informed consent.

•(1) Other tumor history within 5 years;
•(2) Symptomatic brain metastases;
•(3) History of cardiovascular disease: Congestive heart failure & GT; Cardiac function level II in NYHA. Patients with unstable angina (angina symptoms at rest) or newly developed angina (beginning in the last 3 months) or myocardial infarction in the last 6 months. Active infection, & GT; Level 2 adverse events (CTC AE.5.0);
•(4) Patients during pregnancy or lactation;
•(5) Persons with a history of mental illness.

发起方

onghua Hospital, Shanghai University of Traditional Chinese Medicine